 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol
IDs
|
|
|
| |
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma
|
|
|
|
Phase IV
|
|
|
|
ADO-MM-PAL8
NCT00226473
|
|
| |
Characterization of the Melanoma-Specific Immune Response
|
|
|
|
Phase IV
|
|
|
|
200513097-1
NCT00368615
|
|
| |
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
SP-11-0035
NCT00123760
|
|
| |
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
|
|
|
|
Phase III, Phase II
|
|
|
|
CA184-025
NCT00162123
|
|
| |
High-Dose Interferon alfa in Treating Patients With Stage II or Stage III Melanoma
|
|
|
|
Phase III
|
|
|
|
ECOG-1697
SWOG-E1697, CALGB-500103, CAN-NCIC-ME10, COG-E1697, E1697, NCT00003641, ME10
|
|
| |
Adesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma
|
|
|
|
Phase III
|
|
|
|
CCCGHS-NCI-T98-0085
NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682
|
|
| |
A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma
|
|
|
|
Phase III
|
|
|
|
11718
NCT00111007
|
|
| |
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
|
|
|
|
Phase III
|
|
|
|
04-109
NCT00132704
|
|
| |
Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon
|
|
|
|
Phase III
|
|
|
|
MM-ADJ-5
NCT00226408
|
|
| |
PegIntron vs IntronA in CMAJCC Stage II (EADO 2001/CMII Trial).
|
|
|
|
Phase III
|
|
|
|
9267-01
2001-034, NCT00221702
|
|
